INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,224,800 | +2001.7% | 120,000 | +1153.8% | 0.02% | +1600.0% |
| Q2 2023 | $105,855 | +109.5% | 9,571 | +154.3% | 0.00% | – |
| Q1 2023 | $50,537 | +2.2% | 3,763 | -5.9% | 0.00% | – |
| Q4 2022 | $49,455 | -80.2% | 3,998 | -60.5% | 0.00% | -100.0% |
| Q4 2020 | $250,000 | -91.6% | 10,110 | -65.8% | 0.00% | -91.7% |
| Q4 2018 | $2,982,000 | +238.1% | 29,580 | +323.8% | 0.01% | +140.0% |
| Q3 2018 | $882,000 | +21.0% | 6,980 | -19.7% | 0.01% | +25.0% |
| Q2 2018 | $729,000 | +219.7% | 8,688 | +122.6% | 0.00% | +100.0% |
| Q4 2017 | $228,000 | -77.1% | 3,903 | -77.3% | 0.00% | -77.8% |
| Q3 2017 | $997,000 | – | 17,170 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |